ABIVAX (EPA:ABVX) | Finanzwire

PRESS RELEASE

published on 04/01/2026 at 22:05, 7 months ago

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
Abivax publishes financial reports with French and U.S. regulatory agencies, including Universal Registration Document and Annual Report. Company focuses on immune response in chronic inflammatory diseases with lead drug candidate in Phase 3 trials

Abivax Ulcerative Colitis Financial Reports Immune Response Regulatory Agencies
BRIEF

published on 03/27/2026 at 18:05, 7 months 5 days ago

ABIVAX: Details on Share Capital and Voting Rights as of February 28, 2026

Euronext Paris Share Capital Voting Rights Actions Abivax
BRIEF

published on 03/23/2026 at 21:10, 7 months 9 days ago

Abivax presents its 2025 results and outlook

Obefazimod Management Appointments 2025 Financial Results DSMB ABTECT Cash Flow 2027
BRIEF

published on 03/23/2026 at 21:10, 7 months 9 days ago

Abivax Reports Full Year 2025 Financial Results and Business Updates

Financial Results Biotechnology Obefazimod Clinical Trials Leadership Appointments
PRESS RELEASE

published on 03/23/2026 at 21:05, 7 months 9 days ago

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Abivax reports full year 2025 financial results and key business updates, including safety updates, pivotal Phase 3 trial progress, senior leadership appointments, and upcoming milestones. Strong cash position and strategic plans highlighted

Financial Results Abivax Phase 3 Trial Leadership Appointments Business Updates
BRIEF

published on 02/26/2026 at 18:05, 8 months 3 days ago

ABIVAX: Update on Share Capital and Voting Rights

Euronext Paris Share Capital Voting Rights Shares Abivax
BRIEF

published on 02/21/2026 at 12:05, 8 months 8 days ago

Abivax Unveils Promising Obefazimod Data at ECCO 2026

Obefazimod Clinical Efficacy Safety Profile Inflammatory Bowel Disease Anti-Fibrotic Activity
PRESS RELEASE

published on 02/21/2026 at 12:00, 8 months 8 days ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax presents first evidence of anti-fibrotic activity for Obefazimod and new clinical efficacy and safety analyses in inflammatory bowel disease at ECCO 2026

Abivax Obefazimod Clinical Efficacy Inflammatory Bowel Disease Anti-fibrotic
BRIEF

published on 01/26/2026 at 18:05, 9 months 6 days ago

ABIVAX: Share capital and voting rights as of December 31, 2025

Voting Rights Biotechnology Actions AMF Abivax
BRIEF

published on 01/07/2026 at 22:10, 9 months 25 days ago

Abivax unveils its objectives for 2026

Abivax Obefazimod Phase 3 2026 RCH

Published on 10/30/2026 at 23:35, 2 days 3 hours ago

Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 3 hours ago

Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 2 days 6 hours ago

CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 2 days 7 hours ago

Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 11 hours ago

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

View all ACCESSWIRE

Published on 11/01/2026 at 10:35, 16 hours 18 minutes ago

Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 21 hours 53 minutes ago

2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 10 hours ago

SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 4 hours ago

EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 22:30, 2 days 4 hours ago

/C O R R E C T I O N - OCI Global/

View all EQS

Published on 10/30/2026 at 23:00, 2 days 3 hours ago

BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 20:42, 2 days 6 hours ago

TINC and PMV invest in Storm Group (B)
Published on 10/30/2026 at 18:00, 2 days 8 hours ago

2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 14 hours ago

Capital increase through exercise of subscription rights
Published on 10/30/2026 at 08:45, 2 days 18 hours ago

Share buyback

View all LES ECHOS COMFI WIRE

News